Finasteride for hair loss: a review

Gupta, Aditya K.; Venkataraman, Maanasa; Talukder, Mesbah Uddin; Bamimore, Mary A

doi:10.1080/09546634.2021.1959506

Cited by 17 publications

(33 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, both drugs require long‐term applications to observe improvement 1,2 . Some patients experience sub‐optimal improvement due to limited efficacy 1,2 . Additionally, patients on oral finasteride may experience unwanted side effects 2 …”

Section: Introductionmentioning

confidence: 99%

“…The most common cause of losing hair in men is androgenetic alopecia (AGA) 1–3 . Approximately 70% of men suffer from AGA during their lifetimes 1 .…”

Section: Introductionmentioning

confidence: 99%

“…A high DHT level may act on the hair follicle to cause miniaturization 4,5 . Topical minoxidil and oral finasteride are the only FDA‐approved treatments for AGA 1,2 . Oral finasteride is approved for male pattern hair loss only, but it has been used off‐label in postmenopausal women 2 .…”

Section: Introductionmentioning

confidence: 99%

“…Topical minoxidil and oral finasteride are the only FDA‐approved treatments for AGA 1,2 . Oral finasteride is approved for male pattern hair loss only, but it has been used off‐label in postmenopausal women 2 . In contrast, topical minoxidil is approved for both men and women 1 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Natural products for male androgenetic alopecia

Gupta

Talukder

Bamimore

2022

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is the most common cause of hair loss in men, often requiring medical attention. The US FDA approved topical minoxidil and oral finasteride to treat AGA. Topical minoxidil requires a long‐term application to observe improvement; oral finasteride may cause undesirable side effects. Therefore, natural products may be an alternative when patients are skeptical about these two conventional treatments. Physicians may also suggest natural products in conjunction with topical minoxidil or oral finasteride to enhance clinical outcomes. This article reviews the prospect of natural products in treating male AGA. A systematic search was conducted in PubMed, CINAHL, Scopus, Web of Science, and EMBASE (Ovid) on July 19, 2021. In addition, the bibliographies of selected articles were hand‐searched to identify relevant studies. After deduplication and screening, 11 clinical studies meet the criteria for detailed review. The selected clinical studies suggest that saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil might be considered in male AGA treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

“…The most common cause of losing hair in men is androgenetic alopecia (AGA) 1–3 . Approximately 70% of men suffer from AGA during their lifetimes 1 .…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Natural products for male androgenetic alopecia

Gupta

Talukder

Bamimore

2022

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Low‐level laser (FDA approved) and platelet‐rich plasma (PRP) are among the recently used therapeutics for AGA 4,5 6 ; for instance, PRP has been used as a therapeutic in hematology since the 1970s, 7 while topical minoxidil and oral finasteride became FDA approved to treat AGA after 1987 2,3 . Since the publication of Carlos Uebel's work in 2006, 5 the AGA literature has been flooded with studies on PRP’s efficacy 8–18 .…”

Section: Introductionmentioning

confidence: 99%

The effect of placebo in split‐scalp and whole‐head platelet‐rich plasma trials for androgenetic alopecia differs: Findings from a systematic review with quantitative evidence syntheses

Gupta

Bamimore

2022

J of Cosmetic Dermatology

Self Cite

View full text Add to dashboard Cite

Background: Some studies have shown that platelet-rich plasma (PRP) improves androgenetic alopecia (AGA), while others do not. We determined whether the placebo effect significantly varies between split-scalp and whole-head trials on PRP monotherapy for AGA. Our rationale was based on the plausibility of PRP diffusing to the control (i.e., "placebo") side of split-scalp trials. This is not possible in whole-head studies. Methods:We systematically searched the literature for available data. Our choice of analyses and outcomes were determined by the available data.Results: Our endpoint was change in total hair density 6 months after baseline. Our regression showed that total hair density after 6 months was significantly (p < 0.05) higher in the placebo arm of split-scalp trials, compared to whole-head studies, by 37 hairs/cm 2 . Our one-arm meta-analyses showed that the pooled change in total hair density between the PRP side and placebo side in split-scalp studies was −3 hairs/ cm 2 (p = 0.37), that is, a slight decrease in hair density in the placebo side of the scalp.For whole-head studies, the corresponding difference in total hair density between patients receiving PRP and those on placebo was −30 hairs/cm 2 (p = 0.000017), that is, a much larger decrease in hair density. Patients in the placebo group in whole-head trials lost significantly more hair than in the placebo side of the split-head trials where hair loss was comparatively reduced -presumably because of PRP diffusing from the treatment side of the scalp. Conclusions:The association between design (i.e., split-scalp vs. whole-head) and outcome, in placebo arms of AGA trials on PRP monotherapy, had never been reported. This "design effect" could partly reconcile the incongruent conclusions across the PRP literature for AGA; furthermore, clinical guidelines can consider "design effect" when selecting evidence to base care practices on. K E Y W O R D S pattern baldness, placebo effect, platelet-rich plasma, regression analysis, split scalp | 1455 GUPTA And BAMIMORE How to cite this article: Gupta AK, Bamimore MA. The effect of placebo in split-scalp and whole-head rich plasma trials for androgenetic alopecia differs: Findings from a systematic review with quantitative evidence syntheses. J

show abstract

Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia

Zari

2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: This study assessed the levels of compliance to topical minoxidil (TM) among male and female patients with androgenetic alopecia (AGA) and analyzed the factors associated with minoxidil discontinuation. Method: A retrospective study was conducted among 400 consecutive patients with AGA who presented to a dermatology clinic and who were prescribed minoxidil 2% or 5% in the past 5 years. Demographic factors, other previous treatments, and minoxidil parameters including the dose (2% or 5%), total duration of use, treatment results, and side effects were collected. Result: The mean age of the patients was 32.41 years [standard deviation (SD) 8.18], and 66.5% were female. The majority of patients (82.5%) did not receive any previous treatment for AGA. Of the total patients, 345 (86.3%) have discontinued minoxidil. Discontinuation rate showed no association with sex (p = 0.271), age

show abstract

Finasteride for hair loss: a review

Cited by 17 publications

References 76 publications

Natural products for male androgenetic alopecia

Natural products for male androgenetic alopecia

The effect of placebo in split‐scalp and whole‐head platelet‐rich plasma trials for androgenetic alopecia differs: Findings from a systematic review with quantitative evidence syntheses

Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia

Contact Info

Product

Resources

About